Head-to-head: Potent hepatitis B antivirals compared

The drugs appear similarly effective in reducing risk of liver cancer, studies show

Tenofovir and entecavir appear to be equally effective in reducing risk of hepatocellular carcinoma (HCC) and all-cause mortality in people with hepatitis B over five years, a ‘real-world’ study suggests.